Arthritis Development Strategy: Cimzia’s BLA Has More Wiggle Room, But Humira Uses Tougher Endpoint
This article was originally published in The Pink Sheet Daily
Executive Summary
Heading into a July 23 Arthritis Advisory Committee, AbbVie’s Humira brings a robust efficacy showing but also total reliance on a new patient diagnostic mechanism; the product’s supplemental application will be reviewed alongside a similar one for UCB’s Cimzia.